Food News and Research

RSS

Max Planck Innovation licenses new software for metabolite analysis

Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.

28 Oct 2010

YorkTest Laboratories offers testing kit to identify food intolerance

It is estimated that up to 12 million people are living with food intolerance and spending on average up to 350 pounds Sterling on wasted remedies and pills trying to relieve the symptoms before they discover the cause.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

Scientists suggest FDA to reevaluate safety of plant-based antioxidants

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants including those renowned for their apparent ability to prevent cancer may actually aggravate or even cause cancer in some individuals.

28 Oct 2010

Study examines children's tendencies toward food and development of obesity

When it comes to understanding where tendencies to overweight and obesity develop, you have to begin with the very young, says John Spence, a behavioural scientist in the Faculty of Physical Education and Recreation at the University of Alberta.

28 Oct 2010

Federal Government seizes prescription and OTC drug products from Tri-Med Labs

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized articles of prescription and over-the-counter (OTC) drug products from Tri-Med Laboratories Inc. in Somerset, N.J. earlier this month. The seizure warrant, issued by the U.S. District Court for the District of New Jersey and unsealed this week, shows the drugs are unapproved and adulterated new drugs.

28 Oct 2010

High urine BPA levels associated with decreased sperm quality

Increasing urine BPA (Bisphenol-A) level was significantly associated with decreased sperm concentration, decreased total sperm count, decreased sperm vitality and decreased sperm motility, according to a Kaiser Permanente study appearing in the journal of Fertility and Sterility.

28 Oct 2010

Calypso Medical initiates clinical study to evaluate tracking technology for lung tumors

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced the initiation of the first clinical study to evaluate the use of the Calypso System for tracking lung cancer tumors during radiation delivery, including a new design of the Company's implantable Beacon transponder.

28 Oct 2010

Cell Therapeutics 2010 third quarter total net operating expense decreases 52% to $13.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the third quarter ended September 30, 2010.

28 Oct 2010

Report notes potential for African agriculture, European partnerships

A new report highlights concerns about donors, especially from Europe, following through on funding pledges for the G8's $22 billion global food security fund, Business Daily reports.

28 Oct 2010

EpiCept, FDA reach agreement on regulatory path forward for Ceplene

EpiCept Corporation today announced that it has reached an agreement on all outstanding issues with the U.S. Food and Drug Administration (FDA) on a regulatory path forward for Ceplene® (histamine dihydrochloride), the Company's lead product for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission. Ceplene® is approved in the European Union for this indication and is marketed there by Meda AB.

28 Oct 2010

B. Braun initiates voluntary recall of heparin injection products

B. Braun Medical Inc. was recently notified by its supplier, Scientific Protein Laboratories LLC (SPL), of a nationwide recall of a lot of Heparin Sodium USP Active Pharmaceutical Ingredient (API) sold to B. Braun because additional testing of retained crude heparin samples used by SPL to manufacture this single API lot indicated a trace amount of oversulfated chondroitin sulfate (OSCS) contaminant.

From B. Braun Melsungen AG 28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BioDelivery Sciences International, Inc. today announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) which took place on September 14, 2010. At that meeting, agreement was reached on the BEMA Buprenorphine development plan for the treatment of chronic pain.

28 Oct 2010

InVivo Therapeutics completes reverse merger with InVivo

InVivo Therapeutics Corporation a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp.

28 Oct 2010

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus Pharmaceuticals, Inc., a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it received approval from the State Food and Drug Administration ("SFDA") Ethics Committee to commence Phase I human clinical trials of R-Bambuterol Hydrochloride, the Company's proprietary drug candidate for the treatment of asthma.

28 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

US FDA cracks down on importation of unapproved new drugs for personal use

The United States Food and Drug Administration (“FDA”) is cracking down on the importation of unapproved new drugs with regards to personal use. Import Alert #66-41, “Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.” (“IA 66-41”) was most recently published on September 23, 2010. IA 66-41 contains a Red List, a list of importers whose products are automatically detained for FDA violations, of over 400 firms on the charge of importing misbranded unapproved new drugs. Benjamin England, founder of FDAImports.com, LLC and former FDA Compliance Officer, attorney, and Food and Drug Law expert states that “This Import Alert has been expanded to include importers and products of drugs imported strictly for personal use rather than just targeting foreign shippers, which is FDA's normal M.O.”

27 Oct 2010

Procter & Gamble 2010 first quarter net sales increases 2% to $20.1 billion

The Procter & Gamble Company reported first quarter diluted net earnings per share from continuing operations of $1.02 per share, an increase of five percent and above the Company’s guidance range of $0.97 to $1.01.

27 Oct 2010